Phio Pharmaceuticals Corp (PHIO)

[Inoviorulez]

If anyone listened to the CC or has seen the transcript you would know a few nice things about this trial that will be known as 1501.

1. It will be on advanced patients with macular degeneration. Not new mac d patients or mid stage ones, but advanced stage macular degeneration patients

2. The trials are gonna be run under the leadership of Compachiaro at John Hopkins wilmer Eye Institute which is the best top notch eye institute in the United states. Not only that but Dr. Compachiaro and his lab were responsible for discovering that VEGF blocks the inhibition of macular degeneration and currently serves on the scientific advisory board for RXII

3. The Filing of the IND was end of July so trial should be good to start probably September/October. Company says before end of 2015.

4. People don't understand the implication of this trial. If patients are also taking an anti VEGF and RXI-109 shows good reduction of the scars then Rxi can be approached by Regeneron, Roche for possible partnerships with Eylea and Lucentis.